Advertisement

Related Videos

Varsha Gandhi, PhD, on Ibrutinib

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Peter Clark, MA, MD, FRCP: A Payer Perspective

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Advertisement

Advertisement




Jan
01
Today In Oncology
Study Explores Association of GLP-1 RAs With Risk of Obesity-Related Cancers
Noninferiority Shown for Pirtobrutinib vs Ibrutinib in CLL/SLL
Deb Schrag Elected 2027–2028 ASCO President
NSAIDs May Improve Survival in Postoperative ctDNA-Positive Patients With Colon Cancer
Molecular Analysis Reveals Underlying Sex-Linked Multiple Myeloma Progression Patterns
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo